Table 1. Per-allele odds ratios for breast cancer risk by estrogen receptor status.
| Locus | ER-positive cases | ER-negative cases | Observed | Adjusted | ||||||
| SNP | Genotype | Controls | N | OR* | 95% CI | N | OR* | 95% CI | P** | P*** |
| FGFR2 | GG | 10,056 | 4,043 | 1.00 | 1,378 | 1.00 | ||||
| rs2981582 | AG | 12,255 | 6,390 | 1.28 | 1.22–1.35 | 1,828 | 1.08 | 1.00–1.16 | ||
| AA | 3,747 | 2,636 | 1.74 | 1.63–1.85 | 607 | 1.18 | 1.06–1.30 | |||
| per allele | 1.31 | 1.27–1.36 | 1.08 | 1.03–1.14 | 10−13 | <0.001 | ||||
| TNRC9 | GG | 13,295 | 5,970 | 1.00 | 1,789 | 1.00 | ||||
| rs3803662 | AG | 9,705 | 5,553 | 1.25 | 1.19–1.31 | 1,579 | 1.16 | 1.08–1.25 | ||
| AA | 2,026 | 1,451 | 1.48 | 1.37–1.60 | 397 | 1.28 | 1.13–1.45 | |||
| per allele | 1.23 | 1.19–1.27 | 1.14 | 1.09–1.21 | 0.015 | 0.43 | ||||
| MAP3K1 | TT | 13,447 | 6,352 | 1.00 | 1,912 | 1.00 | ||||
| rs889312 | GT | 10,480 | 5,474 | 1.12 | 1.07–1.17 | 1,539 | 1.03 | 0.96–1.11 | ||
| GG | 2,154 | 1,271 | 1.26 | 1.17–1.36 | 370 | 1.20 | 1.06–1.36 | |||
| per allele | 1.12 | 1.09–1.16 | 1.07 | 1.01–1.13 | 0.11 | 0.99 | ||||
| 8q24 | AA | 7,650 | 3,721 | 1.00 | 1,158 | 1.00 | ||||
| rs13281615 | AG | 10,682 | 5,681 | 1.11 | 1.06–1.17 | 1,603 | 0.99 | 0.91–1.07 | ||
| GG | 3,773 | 2,298 | 1.29 | 1.21–1.38 | 623 | 1.09 | 0.98–1.21 | |||
| per allele | 1.13 | 1.10–1.17 | 1.03 | 0.98–1.09 | 0.001 | 0.038 | ||||
| LSP1 | AA | 12,695 | 6,304 | 1.00 | 1,867 | 1.00 | ||||
| rs381798 | AG | 10,995 | 5,485 | 1.04 | 0.99–1.09 | 1,587 | 1.01 | 0.94–1.09 | ||
| GG | 2,322 | 1,281 | 1.19 | 1.10–1.28 | 363 | 1.13 | 1.00–1.27 | |||
| per allele | 1.07 | 1.04–1.11 | 1.04 | 0.99–1.10 | 0.31 | 1.00 | ||||
*: ORs adjusted for study.
**: P for heterogeneity calculated from case-only analyses adjusted for study.
***: Permutation adjusted P for heterogeneity